stockrow
Friday 6 November 2026
Export ZNTL’s income statement to Excel — free account
Zentalis Pharmaceuticals, Inc.
ZNTL Healthcare Biotechnology
Zentalis Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $67.4 million.
- EPS
- −59.5%
- Free cash flow
- −9.06%
Quarter to June 2026, against a year earlier
1.71
0.05
−2.84%
Follow ZNTL
Alert me
Zentalis Pharmaceuticals, Inc. (ZNTL) P/E ratio
Zentalis Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| INO Inovio Pharmaceuticals, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| ORMP Oramed Pharmaceuticals Inc. compare | 0.9× |
| ADAG Adagene Inc. Sponsored ADR compare | — |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)